OBJECTIVE: Th e 6-min walk distance (6MWD), a widely used test of functional capacity, has limited evidence of construct validity among patients surviving acute respiratory failure (ARF) and ARDS. The objective of this study was to examine construct validity and responsiveness and estimate minimal important diff erence (MID) for the 6MWD in patients surviving ARF/ARDS .
Patients who survive acute respiratory failure (ARF) and ARDS frequently experience important and longlasting physical impairments. 1,2 Th e 6-min walk distance (6MWD) is a widely used measure of functional capacity in studies of patients surviving ARF/ARDS. 1 Robust literature on the validity of the 6MWD exists for geriatric, cardiac, neurologic, and COPD populations, [3] [4] [5] [6] [7] [8] [9] but a comprehensive validation of the 6MWD has not been done among patients surviving ARF/ARDS. Th ese patients diff er from chronically ill populations due to acute onset of physical impairments and younger age; therefore, determining the validity, responsiveness, and minimal important diff erence (MID), defi ned as the smallest difference perceivable by patients, for the 6MWD is important for planning and interpretation of future research studies. 10 Th e present study used data from four international longitudinal studies to examine the construct validity of the 6MWD in patients surviving ARF/ARDS.
Materials and Methods

Study Design
Secondary analyses were performed using data from two US-based studies (ARDSNet Long Term Outcomes Study [ALTOS] and Improving Care of Acute Lung Injury Patients [ICAP]) 11, 12 and two Australianbased studies. 13, 14 Patients from these studies with at least one 6MWD assessment in the 12 months aft er critical illness were included. Th e ALTOS included patients surviving ARDS from 12 hospitals across fi ve study sites, with 6-and 12-month follow-up occurring between 2008 and 2012. 11 ALTOS subjects were recruited based on participation in at least one of three co-enrolling National Heart, Lung, and Blood Institute ARDS Network randomized trials evaluating aerosolized albuterol vs placebo (Albuterol to Treat Acute Lung Injury [ALTA] trial), 15 17 Th e ICAP study was a prospective cohort study in patients surviving ARDS recruited from four academic teaching hospitals in Baltimore, Maryland, with 3-, 6-, and 12-month follow-up occurring between 2005 and 2009. 12 Th e Denehy et al 13 study was a blinded randomized trial of intensive rehabilitation across ICU, hospital, and community settings vs usual physiotherapy care in patients with ARF in a single hospital in Melbourne, Victoria, Australia. Patient assessments at hospital discharge and 3-, 6-, and 12-month follow-up between 2008 and 2010 were included in this analysis. Th e Elliott et al 14 study was a blinded randomized trial of an 8-week home-based rehabilitation program conducted in patients with ARF recruited from 12 hospitals across three study sites in Australia. Patient evaluations conducted at 1, 8, and 26 weeks aft er hospital discharge (coded as hospital discharge, 3 and 6 month, for this analysis) between 2005 and 2009 were included in this analysis. In all studies, the randomized interventions did not have an eff ect on physical outcomes, so patients in both arms of each trial were pooled for this analysis. 11, 13, 14, 18, 19 All studies obtained informed consent from participants and were approved by relevant institutional review boards (Johns 20 we use the term "ARDS" rather than "acute lung injury" throughout this article.
Study Measures
Th e primary study measure 6MWD was based on American Th oracic Society guidelines 21 in all studies with modest variations, including using a single 6MWD at each follow-up in the studies (as done in prior ARF/ARDS research 2 ) and using the longest available distance (based on American Th oracic Society guidelines 21 ) during home visits. Th e 6MWD was presented in meters and as % predicted (calculated using US 22 and Australian 23 normative values) for all studies except Elliott et al 14 in which % predicted values were not available.
Well-established performance-based and patient-reported measures refl ecting important aspects of physical functioning (PF) were used to assess convergent and known-groups validity of the 6MWD. Th ese include the 4-m timed walk speed (in meters per second), [24] [25] [26] manual muscle testing using the Medical Research Council sum score 27, 28 (range, 0-60, with , 48 indicating ICU-acquired weakness 29 ), and spirometry 30 (reported as FEV 1 % predicted based on normative values 31 ). Patient-reported measures included the Medical Outcomes Survey 36-Item Short Form (SF-36) 32 PF domain, the Functional Performance Inventory 33 overall score, and the Euro-QOL (EQ-5D) 34 mobility subscale. Th ese measures oft en are used in studies of physical outcomes in patients surviving ARF/ARDS. [35] [36] [37] [38] [39] Well-established patient-reported mental health measures were used to assess discriminant validity, including the SF-36 mental health domain, anxiety subscales of the Hospital Anxiety and Depression Scale 40 and EQ-5D, and the overall posttraumatic stress disorder symptom score of the Impact of Event Scale-Revised. 41 Prior reports of the correlation between physical and mental health measures have been weak (typically, r , 0.3). [42] [43] [44] Hospitalization, mortality, alive-at-home status (whether patients were living at home), return to normal activity (return to work, school, homemaking, or volunteering as was occurring prior to hospitalization), and healthrelated quality of life (HRQL) up to 12 months postdischarge were used to test predictive validity. Data were obtained through patient or proxy report, although medical records were also used in Denehy et al. 13 Hospitalizations occurring within 3 and 6 months can be self-reported with 98% and 96% accuracy, respectively. 45 Mortality data were not available in Elliott et al. 14 Th e normed version of the SF-36 PF domain score, available in all studies, was used to assess responsiveness. Patient rating of global change in PF, administered at 6 and 12 months in the Denehy et al 13 trial, was also used in responsiveness analyses. Th is measure asked patients to rate improvement in their ability to perform daily PF activities using a visual analog scale with 0 indicating no improvement and 10 indicating maximum improvement.
Statistical Analysis
Construct Validity: Pearson correlations were used to examine convergent and discriminant validity. To establish convergent validity, we hypothesized that physical health outcomes would be at least moderately correlated ( r . 0.40) with 6MWD. To establish discriminant validity, we hypothesized negligible to weak relationships ( r , 0.30) between mental health outcomes and 6MWD. Furthermore, we expected the correlation of 6MWD with physical health outcomes to be consistently stronger than with mental health outcomes. For known-groups validity tests, the twosample independent t test was used to determine whether mean 6MWD signifi cantly diff ered in groups based on physical health. We hypothesized that patients with ICU-acquired weakness (manual muscle testing strength score , 48) and impaired pulmonary function (FEV 1 , 70% predicted) would perform signifi cantly worse as determined by 6MWD than patients with greater muscle strength and pulmonary function.
Predictive Validity: We used logistic and linear regression to examine the association of a 30-m diff erence in the 6MWD, refl ecting a meaningful diff erence for 6MWD in other populations. 46 ,47 6MWD at discharge, 3 months, and 6 months were hypothesized to predict future mortality, rehospitalization, alive-at-home status, return to normal activity, and HRQL (SF-36 PF domain and EQ-5D utility) at or by 12 months.
Responsiveness: Linear regression was used to test whether change in 6MWD parallels substantial change observed in related physical outcomes in the same period. We examined responsiveness for three postdischarge periods: discharge to 3 months, 3 to 6 months, and 6 to 12 months. We categorized change in the normed SF-36 PF domain between two time points as negative if scores decreased by Ն 10 points, no change if scores decreased or increased by , 10 points, and positive if scores increased by Ն 10 points. Th e 10-point increment represented 1 SD for the normed SF-36 PF domain and has been identified as an important change by clinical experts. 48 A patient PF improvement rating of . 5 in Denehy et al 13 refl ected substantial improvement. Survivors with a positive change or substantial improvement in PF were expected to walk substantially farther than survivors reporting no change, negative change, or nonsubstantial improvement. We further examined whether change in 6MWD could discriminate between patients reporting substantial improvement from those reporting less improvement by evaluating the area under the receiver operating characteristic curve.
Estimating MID:
We used multiple anchor-and distribution-based methods to estimate the 6MWD MID. 49 Anchor-based methods used the SF-36 PF domain (scale, 0-100) and EQ-5D utility (original 0-1.0 multiplied by 100 for comparison with SF-36). Th ese outcomes were chosen as anchors given their distinct, but important concepts of HRQL (EQ-5D utility includes physical and mental aspects), strong convergent validity with the 6MWD (SF-36 PF, r 5 0.36-0.76; EQ-5D, r 5 0.43-0.65; P , .01), and the availability of previously reported MIDs. To estimate an anchor-based MID, we used a linear regression model with 6MWD as the outcome and the anchor measure SF-36 PF or EQ-5D utility as the predictor. Th e b -coeffi cient from this model represents the number of meters from the 6MWD equivalent to one point in the anchor measure assessed at the same time point. Th e b -coeffi cient multiplied by the anchor's MID (fi ve points for SF-36 PF and 7.4 for EQ-5D [which is the published MID for the utility score 0.074 3 100]) 50,51 determines the 6MWD MID estimate.
For the distribution-based methods, SE of measurement, minimal detectable change at the 90% CI , and 0.50 SD, were calculated as in prior studies. 49, 52, 53 We also evaluated 0.20 SD of 6MWD to refl ect a small eff ect size based on Cohen's 54 criteria.
We conducted analyses separately for each study and for various time points to examine whether fi ndings were consistent despite diff erences in study design, patient characteristics, and time since discharge. Th e preceding analyses were also replicated using 6MWD % predicted (rather than 6MWD in meters), which accounts for diff erences in walk distances across patient age, sex, and physical diff erences. 
Results
Patient age, sex, and BMI were similar, with a range of mechanical ventilation durations and ICU lengths of stay represented across studies ( Table 1 ). 6MWDs at 6 months were modestly higher in the two Australian trials vs the two US studies. Findings for 6MWD % predicted, which accounts for patient age, sex, and physical diff erences, were comparable to those for 6MWD in meters and are reported in e- Tables 1 to 5 .
Construct Validity
Consistently across studies, countries, and follow-up time points, correlations of the 6MWD with other PF measures were moderately strong and were mostly weak to negligible with mental health measures, supporting construct validity ( Table 2 , e- Table 1 ). Knowngroups validity tests further supported construct validity, with signifi cantly shorter distance walked for survivors with ICU-acquired weakness and impaired pulmonary function compared with their higher-functioning counterparts ( Table 3 , e- Table 2 ).
Predictive Validity
Based on pooled analyses, 6MWD can signifi cantly predict future mortality, rehospitalization, alive-at-home status, return to normal activity, and HRQL ( Table 4 , e- Table 3 ). Prediction of 12-month HRQL was particularly consistent across the studies and time points 6MWD was assessed. 6MWD was less consistently associated with the remaining outcomes in the individual studies possibly because of the rarity of these events in some studies.
Responsiveness
Survivors with positive SF-36 PF domain changes walked farther than those reporting no change or negative change ( Table 5 , e- Table 4 ). Th is fi nding was most apparent in the pooled analysis. Positive SF-36 PF domain changes between 3 and 6 months were associated with 6MWD increases of 65 (95% CI, 46-83) m compared with 26 (95% CI, 9-42) m for the no-change group and 2 29 (95% CI, 2 53 to 2 5) m for the negativechange group ( Table 5 ) . Similar results were observed between 6 and 12 months but not for the period from discharge to 3-month follow-up when all three change groups walked substantially longer distances. However, the latter fi nding appears to be largely due to one of the two trials examining this earlier period.
For the patient rating of global change, the group reporting substantial vs modest or no improvement had a larger mean increase in 6MWD between discharge and 6 months (239 
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Each analysis was based on participants with an observation for both outcome and 6MWD at the specifi ed time point. OR for a 30-m increase in 6MWD. hosp. 5
hospital; NA 5 not available . See Table 1 ALTOS and ICAP scores normalized to US general population with mean Ϯ SD of 50 Ϯ 10. Table 1 and 2 legends for expansion of abbreviations. a P Յ .05 for comparison between the positive change group vs the negative change group. b P Յ .01 for comparison between each change group vs the no-change group. c P Յ .05 for comparison between each change groups vs the no-change group.
Estimating MID
Using known MIDs for the SF-36 and the EQ-5D utility score, anchor-based MID estimates for the 6MWD ranged between 14 and 30 m ( Table 6 ) , which was consistent across time points, study, and country. Estimates using the EQ-5D MID were modestly larger than those using the SF-36 MID ( Table 6 , e- Table 5 ). Distribution-based MID estimates were generally larger than anchor-based estimates but were also consistent across time points, study, and country. Specifi cally, the range of estimates for each measure was as follows: SE of measurement, 31 to 38 m; minimal detectable change at the 90% CI, 67 to 88 m; 0.5 SD, 53 to 84 m; and 0.2 SD, 21 to 34 m ( Table 6 , e- Table 5 ).
Discussion
Overall, the 6MWD is a valid measure of functional capacity for patients surviving ARF/ARDS. Consistent evidence of concurrent construct validity was found at various time points postdischarge and across international studies with diff erent patient samples and study designs. Th e 6MWD was also found to have predictive validity and was responsive to changes in PF.
Using recommended methods for estimating MID, 49 we determined that 20 to 30 m refl ects the 6MWD MID. Anchor-based estimates, which were given greater weight, 49 were approximately 20 m and comparable with or only modestly smaller than prior reports for anchor-based MIDs in geriatric patients and patients with COPD. 46, 55 Th e present distribution-based MID estimates were modestly larger than the anchor-based ones but were also consistent with prior studies with geriatric, COPD, and chronic pulmonary disease populations. 47, [55] [56] [57] Identifying a single MID is diffi cult given the challenges in defi ning "minimum." However, the convergence of the present anchor-based estimates with the distribution-based SE of measurement and 0.2 SD 49, 53, 58 suggests that a narrow range of 20 to 30 m would be a reasonable MID for the 6MWD. Overall, anchor-and distribution-based MID estimates were surprisingly consistent across the studied patient populations, settings, and points along the recovery trajectory. Although anchor-based MID may be determined cross-sectionally or longitudinally, 59 the present anchor-based estimates are from cross-sectional, between-group analyses and are most appropriate for group comparisons than for within-subject change.
Th e fi ndings on 6MWD % predicted largely paralleled those from the 6MWD in meters, with evidence of concurrent construct validity, predictive validity, and responsiveness across studies and time points. Similarly, although distribution-based MID estimates were larger than anchorbased MIDs, a narrow range of 3% to 5% predicted 6MWD was observed that likely represents a small but patientperceivable diff erence. Th e similarity of fi ndings for both 6MWD in meters and % predicted suggests that age, sex, and physical attributes (height, weight) do not substantially infl uence the validity of the 6MWD.
Th is study provides a comprehensive validation of 6MWD among patients surviving ARF/ARDS. However, potential limitations to this research exist. First, the selected variables (eg, patient rating of improvement in functioning) were not available in all studies, limiting our ability to replicate or pool data across studies for a small number of the analyses. Second, we relied on the SF-36 PF domain and EQ-5D as anchor measures. Th ese measures assess functioning more broadly and do not
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precisely match the construct assessed by the 6MWD that focuses more specifi cally on walking aspects of functional capacity. Th ird, analyses that require categorization can lead to small sample sizes within specifi c cells. Th e lack of statistical signifi cance for some comparisons in the responsiveness and predictive validity analyses may be due to this issue; however, pooling data across studies generally addresses this problem. Finally, our MID analyses were focused on group-level comparisons, and the fi ndings cannot be extended to intrapatient MIDs. Despite these limitations, an extensive set of similar variables across these four international studies has provided rigorous evaluation of the validity of the 6MWD. Furthermore, the consistency of the fi ndings across diverse study populations, study designs, and time points and for 6MWD evaluated in both meters and as % predicted support generalizability.
Conclusions
Th e 6MWD is a commonly used evaluation of PF in both clinical and research settings. Th is test requires minimal equipment and can be undertaken by patients with various functional abilities. The study demonstrates that 6MWD is a valid measure for clinicians and researchers to assess functional capacity among patients surviving ARF/ARDS. Th e 6MWD MID, which is 20 to 30 m or 3% to 5% predicted, can help clinicians using the 6MWD to assess and interpret the efficacy of research interventions among patients with ARF/ARDS postdischarge.
